Valiant Laboratories Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Share holding
• Capital structures
• Ratio

Mar ' 25	Mar ' 24	Mar ' 23	Mar ' 22	Mar ' 21

Sources of funds

Owner's fund

Equity share capital

43.45

43.45

32.56

16.28

10.50

Share application money

-

-

-

-

-

Preference share capital

-

-

-

-

-

Reserves & surplus

190.93

193.43

67.93

55.18

78.08

Loan funds

Secured loans

59.40

59.40

59.40

60.68

0.35

Unsecured loans

-

-

-

-

-

Total

293.78

296.28

159.89

132.14

88.93

Uses of funds

Fixed assets

Gross block

30.02

41.46

29.97

22.23

19.79

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

-

9.85

-

-

-

Net block

30.02

31.61

29.97

22.23

19.79

Capital work-in-progress

0.17

0.22

0.05

1.45

-

Investments

165.06

118.59

34.03

0.40

-

Net current assets

Current assets, loans & advances

122.04

174.32

148.71

157.74

86.53

Less : current liabilities & provisions

23.50

28.45

52.87

49.67

17.38

Total net current assets

98.54

145.87

95.85

108.07

69.14

Miscellaneous expenses not written

-

-

-

-

-

Total

293.78

296.28

159.89

132.14

88.93

Notes:

Book value of unquoted investments

-

-

0.01

-

-

Market value of quoted investments

-

37.61

34.02

0.40

-

Contingent liabilities

76.07

16.73

0.42

0.87

-

Number of equity sharesoutstanding (Lacs)

434.50

434.50

325.60

162.80

105.00